KROS:NASDAQKeros Therapeutics, Inc. Analysis

Keros Therapeutics (KROS) is trading at $11.15, which sits beneath its 20‑day, 50‑day and 200‑day moving averages (11.38, 13.63, 15.73), confirming a bearish price trend. The RSI of 39 suggests the stock is approaching oversold territory, while the MACD histogram is positive, giving a modest bullish signal. Volume has been trending lower, and the 30‑day price volatility is a steep 69 %, underscoring a high‑risk price environment. Fundamentally, the company’s price‑to‑earnings ratio of 4.85 is dramatically below the biotechnology industry average of 26, and the price‑to‑book of 0.72 indicates a deep discount to book value. However, revenue has collapsed by 87 % year‑over‑year and operating margins are severely negative, reflecting the challenges of a clinical‑stage firm.
A discounted cash‑flow analysis places fair value around $38 per share, implying a potential upside of over 100 % if the company can navigate its pipeline. Recent material news – the appointment of Charles Newton to the board and the presentation of new rinvatercept data at the 2026 MDA conference – provide short‑term catalysts that could tighten the technical picture. The balance sheet is strong, with $287 M in cash versus $17 M of debt, and free cash flow remains positive, giving the firm runway to fund its trials. Given the high regulatory and sector risk inherent in biotech, investors should weigh the upside against the volatility and execution risk. Overall, the stock appears markedly undervalued but contingent on successful clinical outcomes.